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We report here that a neutralizing mouse monoclonal antibody against basic FGF inhibited both anchorage-dependent and anchorage-independent 
growth of U-87MG and T98G human glioblastoma CXIIS and HeLa cells, all of which express both the basic FGF and the FGF receptor genes. 
In addition, the subcutaneous administration of this antibody significantly suppressed the tumor development of these tumor cells in nude mice. 
Therefore, basic FGF plays an important role in neoplastic growth of these cells. The neutralization of basic FGF will be effective in controlling 
the growth of tumcrs, such as glioblastoma and other cancer cells which bear basic FGF and FGF receptors. 
Basic fibroblast growth factor; Fibroblast growth factor receptor; Mouse monoclonal antibody; Glioblastoma; HcLa cell 
1. INTRODUCTION 
Autonomous cell growth and tumorigenesis may 
result from constitutive interaction of cellular growth 
factors with their corresponding receptors [l]. Basic 
fibroblast growth factor (FGF) is a mitogen and a dif- 
ferentiation factor for neuroectoderm-derived cells or 
mesoderm-derived cells [2] as well as a potent 
angiogenic factor [2,3]. We recently demonstrated us- 
ing Northern hybridization that basic FGF was abun- 
dantly produced in 94.4% of human glioma tissues in a 
tumor origin-specific manner [4], Furthermore, a 
number of glioma cells are known to bear FGF recep- 
tors [5,6], and U-87MG human glioblastoma cells have 
been reported to produce and release basic FGF ex- 
tracellularly as an autocrine factor [7]. We have sug- 
gested that glioma-derived basic FGF might be involved 
in their autonomous growth and tumorigcnesis as an 
autocrine growth factor in vivo [4]. In addition, many 
other tumor cells have been previously reported to pro- 
duce basic FGF and to be dependent upon their cellular 
basic FGF [2,8]. In order to determine whether basic 
FGF is responsible for the autonomous growth and 
tumuriyelrtk of human glioblastoma cells and other 
basic FGF expressing cells, we examined the inhibitory 
effect of a neutralizing anti-basic FGF IgG on cell 
growth in monolayer culture, colony formation in soft 
agar and tumorigenesis in nude mice. 
2. MATERIALS AND METHODS 
2.1. CeNs and cell culhtre 
U-87MG and T98G human glioblastoma cells were obtained from 
Riken Cell Bank Inc. and Japan Cancer Research Resource Bank 
Inc., respectively. A43 1 human epidermoid carcinoma cells and HeLa 
cells were kindly provided by K. Lee and K. Tsuboi, respectively. All 
cells were routinely grown in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% (vol/vol) fetal calf serum (FCS, 
depleted of complement activity) at 37°C in an atmosphere of 5% 
CO2/95% air. 
2.2. Arr/ilrody 
As a neutralizing antibody against human basic FGF, 3H3 mouse 
monoclonal antibody (3H3 MOP ’ ,i*ouse IgG class I) was generated 
by immunizing with basic FGF mutein CS23 (supplied by Takeda 
Chemical Industries Ltd.). within which two serine residues are 
substituted for two cystcinc residues at positions 70 and 88 in the 
natural human basic FGF. On a Wcstcrn blot analysis, 3H3 Mohb 
crossrcacted with basic FGFand basic FGFmutein CS23. but without 
acidic FGF, HSTI, cpidermal growth factor or intcrlcukin-2. This an- 
tibody can ncutraliee the cffcct of cxogcnous basic FGF in a dose- 
dcpcndcnt manner; 100 ng/ml of 3H3 MoAb inhibited cnlircly the cn- 
dothclial cell proliferation induced by 2 ng/ml basic FGP 191. 
2.3. Nar/lrem blot unalysis 
Corrcsl)ortdcrrcearl(~re,~s: M. Hntnnnka, Human Cancer Laboratory, 
Dcpartmcnt of Molcculnr Virology, Institute for Virus Rcscarch, 
Kyoto Unlvcrsity, 54 Kawahara-cho, Shogoin, Sakyo-ku. Kyoto GW, 
Japan, Fax: (81) (75) 761 5626 
A/~6rcwlarlorrs: I:QF. fibroblast growth factor 
Cells grown to conflucncc wcrc lyscd III 5 M guanidinium thio- 
cynnatc and total RNA was isolated using 111~ acid guanidinium rhlo- 
cyanate-phenol-chloroform method [IO]. Ten micrograms of 
poly(h)’ RNA sclcctcd using oligo(d’r) ccllulosc affinity 
chromatagtnphy wcrc dcnuturcd In 1 M glyoxo1/50% dimcthyl 
aulfoxidc, frrctionutcd by clcctraphorcris in 1% agarcrc gels and 
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transferred to diazophenylthioether paper (Schleicher and Schuell. mosphere for two weeks. Colonies which were then larger than 60pm 
Inc., Keene, NH). The following cDNA probes were used for in diameter were counted. 
hybridization: human basic FGF (a 0.4.kb BumHI fragment [I I]) and 
human FGF receptor (a 2%kb EcoRI fragment 1121). These probes 2.7. The antitumorigenic activity of anti-basic FGF IgG in nude 
were labeled with [a-‘“P]dCTP by random priming and hybridization mice 
was carried out as previously described [4]. The final washes were per- Cells (6 x 106 cells/mouse) were injected subcutaneously into the 
formed twice under stringent conditions using 0.1 x SSC and 0.5% back of female BALB/c athymic nude mice (5 to 7 weeks old) in 
SDS at 65°C for 30 min each time [4]. Filters were then triplicate or quadruplicatc. Two, four and six days after transplanta- 
autoradiographed for two days at - 70°C using intensifier screens. tion, 3H3 MoAb anti-basic FGF IgG (2OOpg/mouse/day) or normal 
mouse IgG (200 &mouse/day) was injected into the subcutaneous 
2.4. Ilrrmunofluorescence space surrounding the tumor mass. Mice were monitored for the ap- 
Cells were grown on glass coverslips, then fixed with 3.7% for- pearance of solid tumors, and the length and width of the tumors were 
maldehyde in phosphate-buffered saline (PBS) for an hour at 4’C and measured using a caliper every other day. The volume of tumors was 
washed with PBS (5 mitt, twice). The fixed cell monolayers were calculated according to the following formula 191: tumor volume in 
permeabilized with O.lt70 NP-40 in PBS for 10 min at room tem- mm”= length x (width)’ x0.5. After mice were sacrificed, sub- 
perature, washed with PBS three times. After preincubation with nor- cutaneous tumors with surrounding tissues were resected and fixed in 
mal rabbit serum diluted with PBS, 3H3 MoAb mouse monoclonal Bouin’s fixative. The histology of subcutaneous tumor and surroun- 
antibody against human basic FGF (40pg/ml) or non-immune mouse ding tissues was examined in paraffin embedded sections with 
serum was applied to coverslips for one hour at 37°C. After washes hematoxylin and eosin staining. 
with PBS (for 15 min, 3 x), cells were incubated for one hour at 37°C 
with FIX-conjugated rabbit anti-mouse IgG. Then. coverslips were 
washed with PBS (for 15 min, 4x), mounted on glass slides and ex- 
amined in a microscope equipped for epifluorescence. Micrographs 3. RESULTS 
were obtained after exposure of 40-80 s (Kodak Tmax 800 Asa). 3.1. Expression of basic FGF and FGF receptor 
2.5. Cell growth assays Northern blot analysis of basic FGF in T98G cells 
Cells (5 x IO’ cells/well) were grown in DMEM/ and HeLa cells revealed four bands at 7.0, 3.7, 2.3 and 
IO%FCS and seeded in 48-well plates (1 l.3-mm wells, Costar). After 1.5 kb (Fig. l), corresponding to ones previously 
cells had become attached to the substratum, the media was changed 
to fresh DMEhl/IO% FCS containing 3H3 MoAb anti-basic FGF 
reported [I3]. In addition, a 4.2-kb transcript for FGF 
1gG1 (lOOpg/ml), normal mouse 1gG1 (lOO/rg/ml) or no IgG. After 
receptor [14] was detected in T98G cells and HeLa cells 
three days, triplicate cultures were trypsinized and counted with an (Fig. 1). A43 1 cells yielded no transcript for either basic 
improved Neubauer hemocytometer. Cell viability was determined by FGF or FGF receptor. 
dye exclusion test with Trypan blue. 
2.6. Soft agar colony assays 
DMEM/IO% FCS (2 ml) containing 0.5% agarose (SeaPlaque, 
FMC) was added to 35-mm dishes and allowed to solidify. The cells 
of U-87MG, T98G and HeLa cells were trypsinized, suspended in 
DMEM/IO% FCS (I ml) containing 0.3% agarose and 3H3 MoAb 
anti-basic FGF IgGr (lOO&ml) or normal mouse IgGr (lOO/cg/ml), 
and were plated in triplicate at a density of 8x 10” cells per dish. 
A-431 cells were suspended in the medium containing 0.2% agarosc, 
400 pM epidermal growth factor (Receptor grade, Collaborative 
Research Inc.) and anti-basic FGF antibody (100 /(g/m) or normal 
mouse IgGr (lOOpg/mI), and plated in triplicatcat a density of 2 x IOJ 
cells per dish. These cultures were incubated at 37°C in a 5070 CO2 at- 
bosbc FGF FGF receptor 
3.2. Immunofluorescence 
Bright staining was observed mainly in nuclei of 
U-87MG, T98G and HeLa cells while it was not 
detected in A431 cells (Fig. 2). In control experiment, 
no staining was observed when nonimmune serum was 
applied. 
3.3. Inhibition of Anchorage-dependent Growth 
Anti-basic FGF IgG significantly inhibited the 
growth of U-87MG, T98G, HeLa and A431 cells at 
Fig. I I Nor~hcrn hyhritlir.otion of bark FCiI-’ and FGF rcccptor. fen nricragrnmr of paly(A)’ ItNh were loaded 11) raclr ~IoI. 
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Fig. 2. lmmunofluorescence staining with 3H3 MoAb anti-basic FGF 
antibody. Panels A and B show U-87MCi cells; T98G cells, (C,D); 
HcLa cells, (E,F); A431 cells, (G,H); immunofluorcsccnce applied 
with ami-basic FGF IgG (A,C,E,G); control with non-immune rabbit 
serum (O,D,F,H). Sraining is mainly detected in nuclei of U-87MG, 
T98G and HeLa cells while it is nor in A431 cells. 
rates of 34.0% (PcO.05, assessed by r-test), 23.1% 
(P<O.O5), 34.4% (PcO.05) and 84.6570 (not signifi- 
cant), respectively, of cells incubated with normal 
mouse 1gG1 (Fig. 3). At a concentration of lOO~g/ml, 
anti-basic FGF IgG remarkably biockcd the growth of 
U-87MG, T98G and HcLa cells, whereas normal IgG at 
the some concentration did not significantly affect their 
cell growth I 
no IgG 
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Fig. 3. The inhibitory effects of anti-basic FGF IgG on the anchorage- 
dependent growth of U-87MG. T98G. HeLa and A431 cells. Cells 
(5 x IO’ cells/well) were seeded in 48-well plates, and incubated in 
DMEM/IO% FCS with 3H3 MoAb (IOO&ml), normal mouse IgGl 
(ltN~g/ml) or no IgG for three days. The cell numbers of U-87MG. 
T98G, HeLa and A431 cells incubated wilh 3H3 MoAb for three days 
decreased at the rates of 34.0% (PcO.05, assessed by l-test), 23.1% 
(P<O.OS), 34.4Vo (P<O.OS)and 84.6Vo (not significant), respectively, 
compared to those with normal mouse IgGI. 
3.4. Inhibition of anchorage-independent growth 
The sizes of U-87MG, T98G and HeLa cell colonies 
decreased significantly when they were incubated in 
anti-basic FGF IgG (Fig. 4). The numbers of colonies, 
which were larger than 60pm in diameter, of U-87MG, 
T98G and HeLa cells incubated with anti-basic FGF an- 
tibody also decreased at rates of 20.7% (PcO.O5), 
6.6% (PC 0.01) and 12.9% (P<O.OS), respectively, 
compared to those with normal IgGl while those of 
A431 cells did not (Table I). Agarose containing 100 
pg/ml of normal mouse IgGt did not inhibit colony for- 
mation of these cells compared to that containing no 
IgG (data not shown). 
3.5. Inhibition of turnorigenesis in nude mice 
The tumor development of U-87MG, T98G and 
HeLa cells in nude mice was apparently suppressed by 
subcutaneous administration of anti-basic FGF IgG 
(U-87MG, T98G and HeLa cells, PcO.05, assessed by 
the Wilcq,xon rank sum test on the last day indicated in 
Fig. 5A-;C). The mice injected with normal IgG did 
not show the inhibition of tumor development com- 
pared to those without injections (Fig. 5A-C), The 
tumorigcncsis of A431 cells, however, was not sup- 
pressed by injections of a neutralizing antibody. A-43 1 
tumors grew at exponential rates in both groups 
(Fig. SD). 
The sections of tumors of U-87MG, T98G and HcLa 
cells demonstrated that the surrounding capsules of 
67 
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Fig. 4. Effect of anti-basic FGF IgG on the anchorage-independent growth. 8 x 10’ Cells per 35mm dish were suspended in DMEM/lOYo FCS 
containing 0.3% agarosc and 3’13 MoAb (lOO&ml) or normal mouse IgCit (lOO~g/ml). U-87MG cells (A,B), T98G cells (C,D), HeLa cells (E,F) 
and A431 cells (G,H) incubated with normal mouse IgGl (A,C,E,G) or with anti-basic FGF IgC (B,D,F,H) at a concentration of lOO&ml. 
Table I 
Inhibiiion of colony formations by anti-basic FGF IgG 
- 
Cells Number of colonies in the prcscncc of 
-_ 
Normal IgG Anti-basic I:GF IgCi 
U.87MG 4700 960 
T98G 5100 GGO 
HcLo 6700 440 
A431 550 G30 
Normal mouse lgCi~ (IOO~~g/ml) or on&basic IW: IpG was adtlcd 31 
a conccfltratton of IOO~rg/tnl. ‘I’hc colonies, whlclt wcrc Inrgcr than 60 
pm in dianrctcr, wcrc counted. 
tumors, which was composed of collagen fibers and 
fibroblasts originated from hosts, were thinner in the 
groups of mice injected with anti-basic FGF IgG than in 
those injected with normal IgG (Fig. 6). 
4. DISCUSSION 
Anti-basic FGF IgG was oblc to inhibit the an- 
choragc-depcndcnt and anchorage-indcpcndcnt growth 
of U-87MG, T98G and HcLa cells, but was ineffective 
when ndministcrcd to A431 cells. We dcmonstratcd us- 
68 
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Fig. 5. Inhibitory effect of anti-basic FGF IgG on tumor growth on backs of nude mice. Panels show the profiles of tumor volume of U-87MG 
(A), T98G (B), HeLa (C) and A431 cells (D). Tumor cells were injected subcutaneously into mice on day I, On day 3.5 and 7. mice received the 
subcutaneous injection of anti-basic FGF IgG (solid circles, e), normal mouse IgG (open circles, 0) or no IgG (open squares, 0) at a concentra- 
tion of 200 &mouse/day. Vertical lines indicate SD. 
ing Northern blot analysis that T98G and HeLa cells ex- 
pressed both the basic FGF and the FGF receptor genes. 
Immunofluorescence study also revealed the expression 
of basic FGF peptide in U-87MG, T98G and HeLa 
cells. However, the expression of either basic FGF or 
FGF receptor was not detected in A431 cells. These 
results uggest that, U-87MG and T98G and HeLa cells 
require cellular basic FGF for their neoplastic growth in 
vitro. 
Tumorigenesis of the xenograft transplantation of 
U-87MG, T98G and HeLa cells was apparently sup- 
pressed by anti-basic FGF IgG while that of A431 cells 
was not. In addition, the inhibitory effect on the forma- 
tion of tumor capsules, which were composed of 
fibroblasts and connective tissues derived from the 
hosts, was histologically observed in the tumors ad- 
ministered with a neutralizing antibody. These findings 
suggest hat administered anti-basic FGF antibody was 
active in vivo and was able to inhibit host’s reaction as 
well as tumor cells per se through the inactivation of 
tumor-derived basic FGF. Rcccnt reports have in- 
dicated no suppressing of tumorigcnesis in nude mice 
with the intrnvcnous or intraperitoneal administration 
of neutralizing antibodies against human basic FGF 
[lS,lG]. In those reports, although the bioactivity of ad- 
ministrated antibodies was demonstrated to remain in 
blood for several days, the amounts and the distribu- 
tion of neutralizing antibodies in tumor tissues have 
never been evaluated [ 151. The concentration of an- 
tibody in tumor tissues is expected to be less than in 
blood when it is administrated intravenously or in- 
traperitoneally. Therefore, we injected anti-basic FGF 
1gG into the subcutaneous space surrounding tumors in 
order to expose tumor mass directly with adequate con- 
centration of a neutralizing antibody. Such local ad- 
ministration will be more suitable in clinical trials of 
neutralizing antibodies toward brain tumors because 
blood-brain barriers in the central nervous system may 
prevent he sufficient distribution of antibody from the 
blood circulation into the brain parenchyme. 
It has’been sliggested that basic FGF is involved in 
neoplastic growth from the following evidence; agroup 
of oncogenes, such as HST/K-FGF, lNT2, FGFS and 
HST2/FGF6, encodes basic FGF+elated proteins 
[17-221; certain cells can acquire transformed pheno- 
types after transfection of basic FGF gene [23-26). 
Some of these acquired transformed characters, uch as 
colony formation in soft agar, were reversed by the ad- 
69 
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1:ig. 6. HctIl~to~y~jn and cosin-st~illed sections of turnor~ itt nude mice, Sections of U-87MG (A,B), T98G (C,D) anJ HcLa (E,F) W~C taktn from 
n&C mice injcctcd with anti-basic FGf: fgG (I3,D.P) or riortrral tt~ou~c 1gG (A,C,E) (X 100). Arrows S!IOW the width of the ~ul~or CapSUk. 
dition of anti-basic FGF' IgG 1231; and, a nuinber of 
tumor cells produce basic FGF as an auto&x growth 
factor. The release of cellular basic FGF and the in- 
teraction with its surface receptor may result in the ac- 
70 
quisi~ion of the lnalignant ptlenotype. For exampIc, cx- 
ogenous basic FGF is usuatty required for rttc growth of 
normal cells such as normal adrenal cortical cells and 
myobtast cells [8]. 811 the other hand, the proliferation 
Volume 288, number 1,2 FEBS LETTERS August 1991 
of Y-l mouse adrenal cortical tumor cells and A204 
rhabdomyosarcoma cells become independent of ex- 
ogenous basic FGF because of the acquisition of the 
capacity to produce and to respond to endogenous 
cellular basic FGF [8,27]. A lack of the typical signal 
peptide in basic FGF remains its release mechanism 
unknown [2]. However, the actual release of basic FGF 
into the conditioned media or the extracellular matrix 
was demonstrated in U-87MG glioblastoma cells [7], 
PC13 embryonal carcinoma cells [28] and bovine en- 
dothelial cells [29]. Such mechanism as cell lysis or 
leakage may be involved in the release of basic FGF 
since the existence of similar mechanisms has been pro- 
posed for interleukin-1, another growth factor that 
lacks a signal peptide [30-321. 
Our previous study has demonstrated that 94.4% of 
human gliomas produce basic FGF abundantly in vivo 
[4], while platelet-derived growth factor A-chain, one 
of the suggestive autocrine factors, is expressed in 
38.9% (data not shown). Glioma cells are also known to 
bear cell surface receptors of FGF [5,6]. These suggest 
that basic FGF plays an important role in tumorigenesis 
of gliomas as an autocrine growth factor. In the present 
study, we clearly showed that the blockage of an in- 
teraction of basic FGF with its receptor resulted in the 
inhibition of growth in vitro and tumorigenesis in vivo 
of tumor cells. Thus, the inactivation of basic FGF will 
bring to control neoplastic growth of tumor cells depen- 
ding on basic FGF as an autocrine growth factor and/or 
a paracrine factor. 
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